Jim Cramer Discussed These 18 Stocks As Inflation Dropped

5. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders In Q3 2024: 106

Eli Lilly and Company (NYSE:LLY) has been one of Cramer’s most-discussed stocks this week. Throughout the week, the host covered JPMorgan’s healthcare conference, during which he also conducted an interview of Eli Lilly and Company (NYSE:LLY)’s CEO David Ricks. Despite the fact that the stock fell by 6.6% after the firm’s midpoint 2025 revenue growth guidance of 32% and Q4 Zepbound and Mounjaro sales guidance of $1.9 billion and $3.5 billion missed analyst estimates of $2.08 billion and $5.35 billion, Cramer believes that the stock is a good buy. Here are his latest remarks:

[LLY falling after fourth-quarter guidance]”I thought it was very interesting what David said was they botched the launch so to speak. But even with a botched launch, they were the second biggest earnings beat in history after Jensen Huang’s NVIDIA.

“I think that Lilly is going to be traded, trading off of approvals from now on. You’ll see hypertension, you’ll see [an] incidence of cardio. You might see some things involving joints. You might see [a] heavy drinking trial going on. You might see trial after trial and success after success, and I think you’re getting one more chance. Against that David and I know you care about this passionately, people are telling me it’s got a head and shoulders chart. You know it’s a chart that’s driven the market as well as the quantum computing, obviously that’s what’s in favor, Lilly against. But I think it’s just is a great opportunity, because the numbers are not going to be the focus. The focus will be approvals, and then ultimately payers. I think every major insurer is going to be paying for GLP-1s and that’s why you own the stock. Not because of the fourth quarter.